CRISPR-Cas9 Milestones: The First <em>In Vivo</em> Clinical Trial Is Now Underway
Summary

In a contributed article published by Pharma’s Almanac, Dr. Lydia Michaut of BioAgilytix discusses CRISPR-Cas9 genome editing technology to understand its promising benefits and the potential challenges of anti-Cas9 immunity.

Click for full article

Share This